comparemela.com

Page 5 - Antiviral Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NIH announces antiviral drug development awards

NIH announces antiviral drug development awards
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkMemorial sloan kettering cancer centerNew jerseyStanford universityHackensack university medical centerLa jollaSan franciscoAlpha leeAnthonys fauciPei yong shiJohn choderaJeffrey glennDavid perlinBen perryReuben harris

NIH awards $577 million to establish AViDD Centers for Pathogens of Pandemic Concern

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

United statesNew jerseyStanford universityHackensack university medical centerLa jollaSan franciscoAnthonys fauciEmily hendersonPei yong shiJeffrey glennDavid perlinReuben harrisNevan kroganRichard plemperSumit chandaUniversity of california

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

BOSTON, May 18, 2022 /PRNewswire/ PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National

United statesPrnewswire posteraKostenloser wertpapierhandelAlpha leeInfectious diseases antiviral program for pandemicsNational institutes of healthDrugs for neglected diseases initiativeAntiviral program for pandemicsMemorial sloan kettering cancer centerNational institutesNeglected diseases initiativeMemorial sloan kettering cancerNational instituteInfectious diseases antiviral programStructure enabled antiviral platformChief scientific officer

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

/PRNewswire/ PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration.

Alpha leeNational institutes of healthAntiviral program for pandemicsChief scientific officerNational institutesAntiviral drug discoveryAntiviral program

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

BOSTON, May 18, 2022 /PRNewswire/ PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today

United statesPrnewswire posteraAlpha leeInfectious diseases antiviral program for pandemicsNational institutes of healthDrugs for neglected diseases initiativeAntiviral program for pandemicsMemorial sloan kettering cancer centerNational institutesNeglected diseases initiativeMemorial sloan kettering cancerNational instituteInfectious diseases antiviral programStructure enabled antiviral platformChief scientific officerAntiviral drug discovery

vimarsana © 2020. All Rights Reserved.